GSEP
BEAM icon

Golden State Equity Partners’s Beam Therapeutics BEAM Stock Holding History

Golden State Equity Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$595 Buy
+25
New +$694 ﹤0.01% 1859
2024
Q4 		– Sell
-260
Closed -$6.37K – 487
2024
Q3 		$6.37K Buy
+260
New +$6.72K ﹤0.01% 624
2022
Q1 		$555K Buy
9,690
+3,090
+47% +$203K 0.28% 101
2021
Q4 		$526K Buy
+6,600
New +$565K 0.27% 88

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Golden State Equity Partners's BEAM Position: Q1 2026 in Review

Golden State Equity Partners opened a new position in Beam Therapeutics (BEAM) in Q1 2026: 25 shares worth $595. The stake represents ﹤0.01% of the portfolio and ranks #1859 among its holdings. This is a return to the name: Golden State Equity Partners previously reported a position in BEAM as recently as Q3 2024.

Golden State Equity Partners first reported a position in BEAM in Q4 2021 and has held it in 4 quarters since. The position peaked at $555K in Q1 2022. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Golden State Equity Partners held 25 shares of Beam Therapeutics worth $595 as of Q1 2026.
  • Beam Therapeutics was a new Golden State Equity Partners position in Q1 2026.
  • Beam Therapeutics made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #1859 holding.
  • Golden State Equity Partners first reported a position in Beam Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • Golden State Equity Partners's Beam Therapeutics position peaked at $555K in Q1 2022.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.